Interpace Biosciences (STU:PF42) Total Liabilities : €67.42 Mil (As of Mar. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Interpace Biosciences Total Liabilities?

Interpace Biosciences's Total Liabilities for the quarter that ended in Mar. 2024 was €67.42 Mil.

Interpace Biosciences's quarterly Total Liabilities declined from Sep. 2023 (€72.08 Mil) to Dec. 2023 (€68.49 Mil) and declined from Dec. 2023 (€68.49 Mil) to Mar. 2024 (€67.42 Mil).

Interpace Biosciences's annual Total Liabilities increased from Dec. 2021 (€71.55 Mil) to Dec. 2022 (€74.62 Mil) but then declined from Dec. 2022 (€74.62 Mil) to Dec. 2023 (€68.49 Mil).

Interpace Biosciences Total Liabilities Historical Data

The historical data trend for Interpace Biosciences's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Interpace Biosciences Total Liabilities Chart

Interpace Biosciences Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

26.86

61.46

71.55

74.62

68.49

Interpace Biosciences Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Liabilities	Get a 7-Day Free Trial															73.24	72.13	72.08	68.49	67.42

Interpace Biosciences Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Interpace Biosciences's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	16.024	+	(5.241	+	47.228
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	68.49

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	11.94	-	-56.553
	=	68.49

Interpace Biosciences's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	17.455	+	(2.486	+	47.479
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	67.42

Total Liabilities	=	Total Assets (Q: Mar. 2024 )	-	Total Equity (Q: Mar. 2024 )
	=	11.171	-	-56.25
	=	67.42

Interpace Biosciences Total Liabilities Related Terms

Thank you for viewing the detailed overview of Interpace Biosciences's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Interpace Biosciences (STU:PF42) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Interpace Biosciences Inc (STU:PF42) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

IDXG:USA

Address

300 Interpace Parkway, Morris Corporate Center 1, Building C, Parsippany, NJ, USA, 07054

Website

https://www.interpace.com

Interpace Biosciences Inc is engaged in the life sciences industry. It provides molecular diagnostics, bioinformatics, and pathology services for the evaluation of the risk of cancer by leveraging the latest technology in personalized medicine for improved patient diagnosis and management. The company develops and commercializes genomic tests and related first-line assays principally focused on the early detection of patients with indeterminate biopsies and at high risk of cancer using the latest technology. It operates under one segment which is the business of developing and selling diagnostic clinical services.

Interpace Biosciences (STU:PF42) Headlines

No Headlines